

Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Aclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
Medicines for juvenile joint diseases Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Juvenile idiopathic arthritis

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Alteplase

Section	Indications
Thrombolytic medicines Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection	Cerebral ischaemic stroke

Amodiaquine - sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > Medicines for chemoprevention Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package	Malaria

Amoxicillin

Section	Indications
Access group antibiotics Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	First choice Periapical abscess without sinus

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Second choice Other specified prophylactic measures
Antituberculosis medicines Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Multi-drug resistant Mycobacterium tuberculosis

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Aprepitant

Section	Indications
Antiemetic medicines Oral > Liquid: 125 mg powder for oral suspension (in sachet) Oral > Solid > capsule: 80 mg; 125 mg; 165 mg	Nausea or vomiting

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Azithromycin

Section	Indications
Watch group antibiotics Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)	First choice Typhoid fever Paratyphoid fever

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Carbetocin

Section	Indications
Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to **methimazole** for

Thyrotoxicosis

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Malignant neoplasms of cervix uteri

Cefazolin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures

co-prescribed with **metronidazole**

Other specified prophylactic measures

Ceftazidime + avibactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Typhoid fever

Paratyphoid fever

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Indications

First choice

Typhoid fever

Paratyphoid fever

Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cyclophosphamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

Indications

Plasma cell myeloma

Dabigatran

Section

Medicines affecting coagulation

Oral > Solid: 110 mg; 150 mg

Indications

Venous thromboembolism

Other specified atrial fibrillation

Dengue vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Dexamethasone

Section

Hormones and antihormones

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 4 mg (as dexamethasone base)

Indications

Plasma cell myeloma

Diazoxide

Section

Medicines for hypoglycaemia

Oral > Liquid: 50 mg per mL

Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Plasma cell myeloma

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Enzalutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [abiraterone](#) for

Malignant neoplasms of prostate

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Fexinidazole

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis Oral > Solid: 600 mg	Gambiense trypanosomiasis
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid: 600 mg	Gambiense trypanosomiasis

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Carbapenem resistant <i>Acinetobacter baumannii</i> Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant Enterobacterales

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	Second choice Other specified prophylactic measures

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 20 mg granules Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

Glycopyrronium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

[Chronic obstructive pulmonary disease](#)

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

[Axial spondyloarthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Crohn disease site](#)

Therapeutic equivalent to [adalimumab](#) for

[Rheumatoid arthritis](#)

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

[Juvenile idiopathic arthritis](#)

Imipenem + cilastatin

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for

[Multi-drug resistant Mycobacterium tuberculosis](#)

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

[Axial spondyloarthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Crohn disease site](#)

Therapeutic equivalent to [adalimumab](#) for

[Rheumatoid arthritis](#)

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

[Juvenile idiopathic arthritis](#)

Ivermectin

Section

Medicines for ectoparasitic infections

Oral > Solid > tablet: 3 mg

Indications

Scabies

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Indications

Methicillin resistant Staphylococcus aureus

Vancomycin resistant Staphylococcus aureus

Vancomycin resistant Enterococcus

Lisinopril + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

Essential hypertension

Lisinopril + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

Essential hypertension

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Meropenem

Section

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Methimazole

Section

Thyroid hormones and antithyroid medicines

Oral > Solid > tablet: 5 mg; 10 mg

Indications

Thyrotoxicosis

Metronidazole

Section

Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

First choice

co-prescribed with cefazolin

Other specified prophylactic measures

Multiple micronutrient powder

Section

Vitamins and minerals

Sachets containing:

- iron (elemental) 12.5 mg (as coated ferrous fumarate)
- zinc (elemental) 5 mg
- vitamin A 300 micrograms
- with or without other micronutrients at recommended daily values

Indications

Iron deficiency anaemia

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Indications

Melanoma of skin

Oral rehydration salts - zinc sulfate

Section

Medicines used in diarrhoea

Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)

Indications

Diarrhoea

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Malignant neoplasms of cervix uteri

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Pembrolizumab

Section

Immunomodulators

Indications

Therapeutic equivalent to [nivolumab](#) for

Melanoma of skin

Phenoxymethylpenicillin

Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

Periapical abscess without sinus

Plazomicin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxin B (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Prednisolone

Section

Hormones and antihormones

Oral > Solid: 5 mg; 25 mg

Indications

Plasma cell myeloma

Malignant neoplasms of prostate

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [prednisolone](#) for

Plasma cell myeloma

Therapeutic equivalent to [prednisolone](#) for

Malignant neoplasms of prostate

Procarbazine

Section

Cytotoxic medicines

Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 500 mg + 25 mg tablet

Antimalarial medicines > Medicines for chemoprevention

Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Enterococcus*

Telmisartan + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

Essential hypertension

Telmisartan + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

Essential hypertension

Thalidomide

Section

Immunomodulators

Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tiotropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 18 µg in capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler

Indications

Chronic obstructive pulmonary disease

Tranexamic acid

Section

Other medicines administered to the mother

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Postpartum haemorrhage

Umeclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease